



FOOD AND DRUG ADMINISTRATION
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

MEMORANDUM

DATE : March 24, 2006

FROM : William Freas, Ph.D. /S/
Director, Division of Scientific Advisors & Consultants,
CBER

SUBJECT: Waiver of General Applicability under 18 U.S.C.
208 (b) (3) for John Boslego, M.D.

TO : Jason D. Brodsky
Acting Associate Commissioner for External Relations
Food and Drug Administration

Through: Jenny Slaughter, Director
Ethics and Integrity Staff, Office of Management
Programs, OM

I am writing to request a general matters waiver for John Boslego, M.D., a consultant of the Vaccines and Related Biological Products Advisory Committee at the May 19, 2006 Office Site Visit Subcommittee meeting. This memorandum constitutes a determination that the need for Dr. Boslego's services on the Subcommittee outweighs the potential for a conflict of interest created by any personal or imputed financial interest that he may have in matters of general applicability in which he is expected to participate on the Committee. 18 U.S.C. 208(b) (3).

The Subcommittee will review the intramural research programs in the Office of Vaccines Research and Review (OVRR). The purpose of the Subcommittee review is to make recommendations to further the management of dynamic, responsive, and cutting edge research programs in OVRR that facilitates more efficient development of safe and effective biological products. It is expected that the Subcommittee will focus largely, if not exclusively, on matters of general applicability, as opposed to matters involving specific parties or matters that uniquely and distinctly affect any particular person or organization.

These matters may affect certain financial interests of Dr. Boslego's or of persons and organizations with which he may have certain relationships. This would include:

Financial investments in medical product companies, food related companies, drug related companies, health care industry, and any other industry that might be affected by the recommendations of the Committee, for example, his stock [REDACTED]

Employment with research institutions, state and local governments, medical product manufacturers, food related companies, drug related companies, health care industry or other organizations that may be affected by the Committee's recommendations, for example, the Program Appropriate Technology and Health (PATH) where he is currently employed. Also, included is his consulting with [REDACTED] on pandemic flu preparedness where he receives no compensation, and his consulting with the [REDACTED] regarding the pandemic flu where he receives no compensation. Dr. Boslego was recently employed by Merck as the Executive Director, Biologics - Clinical Research from October, 1995 until February 1, 2006.

Grants, contracts or other funding for research or other services received from the federal government that might be affected by the Committee's recommendations (no interests currently reported);

Grants, contracts or other funding for research or other services received from non-federal sources, including industry and foundations, that might be affected by the Committee's recommendations (no interests currently reported);

Expert witness, litigation or advocacy services in matters that might be affected by the recommendations of the Committee (no interests currently reported);

Any interest of a group or other organization in which Dr. Boslego is appointed as an officer, director, trustee, employee or general partner that might be affected by the Committee's recommendations (no interests currently reported).

Under 18 U.S.C. 208, Dr. Boslego may not participate in any particular matter affecting these interests, unless he receives a waiver. However, pursuant to my authority to grant waivers under 18 U.S.C. 208(b)(3), I have determined that the need for the services of John Boslego, M.D. on this Committee, with respect to matters of general applicability, outweighs any concern that these types of interests might create a potential for a conflict of interest. Consequently, Dr. Boslego may participate in matters of general applicability affecting any current and future financial interests of the types described above. This determination is based on the following considerations:

The Food and Drug Administration has a particularly strong need for Dr. Boslego's service. Dr. Boslego is Director of Program Appropriate Technology and Health. He is an expert in bacterial and infectious diseases, with special expertise in communicable diseases. He has published over 100 medical research articles.

Furthermore, the Committee Charter requires the appointment of individuals who are authorities knowledgeable in a variety of scientific and medical professions. Consequently, it is expected that persons qualified to serve on the Committee will have interests, financial and otherwise, in the work of the Committee. This includes not only employment interests, but also investment and pension interests, as experience has shown that persons employed in the biomedical area frequently acquire investment and pension interests in organizations related to their expertise. In short, financial interests simply are unavoidable in view of the work and membership requirements of the Committee.

Likewise, the very diversity of interests required by the Charter will ensure that no one member is in a position to determine policy in favor of any one affected interest. In addition to the specific requirements of the Charter, the Federal Advisory Committee Act requires fair balance and openness, which serves as important checks against real or apparent threats to the objectivity of Committee action.

Finally, the Committee is expected to focus mainly on matters of general applicability, rather than matters involving specific parties. It is well-recognized that such general matters pose less risk of a conflict of interest. Matters of general applicability include regulations, legislation, and policies governing classes of organizations, individuals, and products.

However, this does not include matters involving specific parties, such as specific grants (as opposed to general recommendations for increased funding in a given area), contracts, product approval applications, or enforcement matters involving known parties.

Please note that this waiver is limited to general matters. It will not allow Dr. Boslego to participate in any matters involving specific parties that may affect his financial interests, or any person or organization described above. If the work of the Committee turns from matters of general applicability to more

